Business
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology LANGHORNE, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for hea
About this update from Nexgel, Inc
[{"type":"image","alt":"NEXGEL, INC.","displaySize":"","headline":null,"caption":"NEXGEL, INC.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":66,"url":"https://media.zenfs.com/en/globenewswire.com/7f0d3c847df57a7d87b54e7056dbb4aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ONAbP5tUr9hDfjARTjK8NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7f0d3c847df57a7d87b54e7056dbb4aa","width":250,"height":66}},"lazy":false},{"type":"text","content":"NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off","length":133,"tagName":"p"},{"type":"text","content":"NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology","length":110,"tagName":"p"},{"type":"text","content":"LANGHORNE, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the spin-off of select drug delivery application assets into NexGelRx, an entity which will focus exclusively on developing and commercializing prescription (Rx) drug delivery solutions utilizing NEXGEL’s proprietary hydrogel technology. At the time of the spin-off, NexGelRx also closed an initial funding from outside investors.","length":636,"tagName":"p"},{"type":"text","content":"Under the terms of the license agreement, NEXGEL will receive a 5% royalty, in perpetuity, for the global rights to its technology for Rx drug delivery by NexGelRx. NEXGEL will also retain a 19.99% equity stake in NexGelRx, which is non-dilutive for up to $8 million of capital investment into NexGelRx. Nexgel will also be the exclusive manufacturer of hydrogel for NexGelRx.","length":376,"tagName":"p"},{"type":"text","content":"Adam Levy, CEO of NEXGEL, commented, “There are multiple medical device drug delivery applications through our unique and proprietary hydrogel technology that has shown promising data to date. This spin-off provides potential return on investment for our shareholders through a dedicated team and platform to pursue high-value Rx opportunities while NEXGEL remains focused on c...